The future of drug targeting and predictive medicine…

A variety of drugs are required for the treatment of the numerous types of cancer. Different cancers respond differently to different drugs. Even different patients with the same cancer type respond differently to the same drug. In some cases, cancer cells develop a resistance to drugs which are initially effective in treating the disease. To address these challenges, Endocyte is developing a portfolio of targeted drugs to provide the most effective therapy for each cancer type. Six of these agents are currently being evaluated in human clinical trials.

Our initial focus is on folate-receptor-targeted therapies for the treatment of cancer. Folate is required for cell division and rapidly dividing cancers over-express special folate receptors to capture more folate from the bloodstream. We take advantage of this by delivering potent cell-killing drugs specifically to these receptor sites.

We are also developing targeted therapies for other cancer-cell receptors and other diseases. An essential part of our strategy is the use of companion diagnostic imaging agents like EC20 and EC0652 to predict whether the drug will reach the sites of disease (see predictive medicine).

click to enlarge